Big Data analytical tools project

Big Data analytical tools project

Health Innovation Technology Transfer (HITT) is working on the development of an European project in Big Data tools. This project tries to understand the needs of the professionals that use Big Data tools in its analytical procedures. In order to know which are the needs and the characteristics of the companies that use Big Data analytical tools, HiTT is developing this study through interviews to professionals of different sectors and also, through on-line questionnaires that people that is interested in this topic can answer. We would like to gather as much information as possible to ensure that our analysis reflects the real concerns of the market. HiTT invites the professionals that use big data tools in its analytical procedure, to open this link and answer the questionnaire. Your responses will be kept anonymous. Many thanks in...
ISPOR 20th annual European congress

ISPOR 20th annual European congress

From 4th to 8th November 2017 it will be held in Glasgow, Scotland, the ISPOR 20th annual European congress. ISPOR is recognized globally as the leading scientific and educational organization for HEOR (health economics and outcomes research) and its use in health care decisions. ISPOR Glasgow provides a forum for discussion and dissemination of HEOR information. The congress is a great opportunity collaborate and network with colleagues in the field, and hear about innovative research methods and new health policy developments. Reflecting on revolutionary transformations affecting today’s health care, ISPOR Glasgow will address medical technology development, health technology assessment, and policy and clinical decision making while exploring the theme, The Evolution of Value in Health Care. Dr. Sola Morales will discuss about the topic that in 1999, the EU enacted legislation to foster the introduction of new Orphan Medicinal Products (OMP) into the market. To date only partial evaluations of the success of this legislation have been made, so this analysis investigates the outcomes of the OMP legislation from a broader perspective. It is possible to find the program in this...
Assessing the Value of New Antibiotics

Assessing the Value of New Antibiotics

Dr. Solà-Morales Serra has participated in the formulation of a new study called, Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions. The study wants to highlight the key challenges with the current approaches to assessing the clinical, economic and health system value of antibiotics. The study faces the actual approaches, and proposes additional elements of value that address these challenges from all relevant perspectives. To conclude the analysis, the paper suggests the next steps needed to refine and implement the additional concepts proposed. This paper was developed by a project team, which included partners from the pharmaceutical industry. The brienfing is available in this web...
Drug’s public procurement study

Drug’s public procurement study

Dr. Solà-Morales Serra has participated in the formulation of a new study that explains the innovative approach of drug’s public procurement. This study analyses the sharing agreements, and the payments in exchange of results. The study provides also an indicative guide that helps to identify which approach or approaches are the most recommended to each situation. The study describes too, the most used solutions in the European industry. The study is available in the following web address: http://www.ieseinsight.com/fichaMaterial.aspx?pk=139748&idi=1&origen=3&ar=7&buscador=2&keywords=&autores=&titulo=&referencia=&fPublicacionMesInf=&fPublicacionAnyoInf=&fPublicacionMesSup=&fPublicacionAnyoSup=&idiomaB=&idiomaBT=&area=&tipo=&tipoT=&deps=&publicadoPor=&catedra=CRHIM+-+Center+for+Research+in+Healthcare+Innovation+Management  ...
Genetic Therapy and the Industrial Uncertainties

Genetic Therapy and the Industrial Uncertainties

Last week, EMA approved Strimvelis for the treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID). It is the second genetic therapy approved by EMA after Glybera was cleared in 2012. The usual discussion goes around rarity, investment and pricing, which have been set at very high levels with a few unknowns on efficacy and long term safety. Let alone the price and the efficiency, the social need and the safety concerns, I would like to raise a parallel question, from the industrial and economic perspective. If the EU has invested so much in genetic research, is still investing in transferring technologies that will enable more gene therapy, shouldn’t we have some more clarity on how we’re going to pay for this? The contradiction is obvious: why accumulate technologies for which we are never going to pay for? Or alternatively, if the strategy is to generate competition to break monopolies, will these companies resist the desert valley? If there is no industrial reward, how are we going to raise money to fund RnD? I guess it is time to discuss about how to proceed with this. The uncertainties are great, the clinical risks unknown, the future developments an unrevealed promise, but yet we should discuss how to look after this emerging industry, or have some kind of mid term...